妊娠期高血压疾病筛查:美国预防服务工作组更新版证据报告与系统综述
本系统综述更新了妊娠期高血压疾病筛查有效性的证据,检索2014年1月1日至2022年1月4日文献并监测至2023年2月21日。纳入6项质量一般的研究(5项试验和1项非随机研究,N=10 165),比较替代筛查策略与常规产前门诊血压筛查。未发现替代策略较常规护理在母婴并发症上有统计学显著差异,但严重罕见结局的估计不精确;需要进一步研究识别可改善疾病检测和健康结局的筛查方法。
要点
- 替代筛查策略(家庭血压监测、减少产检次数、指征性蛋白尿筛查)与常规产前门诊血压筛查相比,未报告母婴并发症的统计学显著差异。
- 家庭血压监测未与妊娠期高血压疾病更早诊断相关(104.3 vs 106.2天)。
- 不同筛查策略未发现危害;严重罕见结局的估计不精确。
核心结论
- 本综述未发现任何替代筛查策略较常规产前门诊血压测量更有效的证据。
- 妊娠期高血压疾病的发病和死亡可以预防,但美国印第安人/阿拉斯加原住民和黑人经历不成比例的不良结局。
- 需要进一步研究识别可能改善疾病检测和健康结局的筛查方法。
研究设计与样本
- 针对美国预防服务工作组进行的靶向系统综述,检索MEDLINE和Cochrane对照试验中心注册库2014年1月1日至2022年1月4日发表的英文比较有效性研究,并监测至2023年2月21日。
- 纳入6项质量一般的研究(5项试验和1项非随机研究;N=10 165),比较产前筛查实践的改变与常规护理(常规亲自到诊所就诊筛查)。
- 两名评价员独立评估文章并从质量一般或良好的研究中提取数据;未进行定量合成。
主要发现
- 1项试验(n=2521)评估家庭血压测量作为常规护理的补充;3项试验(总n=5203)评估减少产前检查次数。
- 1项研究(n=2441)评估仅针对特定临床指征进行蛋白尿筛查,与接受常规蛋白尿筛查的历史对照组比较;另1项试验(n=80)仅涉及家庭血压测量的比较危害。
- 研究未报告替代策略与常规护理相比在母婴并发症上有统计学显著差异,但严重罕见健康结局的估计不精确。
- 家庭血压测量加入产前检查与妊娠期高血压疾病更早诊断无关(104.3 vs 106.2天),在3项减少产前检查次数的试验中两组发病率无差异。
- 未发现不同筛查策略的危害;没有研究涉及产后新发妊娠期高血压疾病的筛查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究未报告替代策略与常规护理相比在母婴并发症上有统计学显著差异;然而,严重、罕见健康结局的估计不精确。
- 需要进一步研究识别可能改善疾病检测和健康结局的筛查方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hypertensive disorders of pregnancy are a leading cause of pregnancy-related morbidity and mortality in the US. OBJECTIVE: To conduct a targeted systematic review to update the evidence on the effectiveness of screening for hypertensive disorders of pregnancy to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE and the Cochrane Central Register of Controlled Trials for relevant studies published between January 1, 2014, and January 4, 2022; surveillance through February 21, 2023. STUDY SELECTION: English-language comparative effectiveness studies comparing screening strategies in pregnant or postpartum individuals. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently appraised articles and extracted relevant data from fair-or good-quality studies; no quantitative synthesis was conducted. MAIN OUTCOMES AND MEASURES: Morbidity or mortality, measures of health-related quality of life. RESULTS: The review included 6 fair-quality studies (5 trials and 1 nonrandomized study; N = 10 165) comparing changes in prenatal screening practices with usual care, which was routine screening at in-person office visits. No studies addressed screening for new-onset hypertensive disorders of pregnancy in the postpartum period. One trial (n = 2521) evaluated home blood pressure measurement as a supplement to usual care; 3 trials (total n = 5203) evaluated reduced prenatal visit schedules. One study (n = 2441) evaluated proteinuria screening conducted only for specific clinical indications, compared with a historical control group that received routine proteinuria screening. One additional trial (n = 80) only addressed the comparative harms of home blood pressure measurement. The studies did not report statistically significant differences in maternal and infant complications with alternate strategies compared with usual care; however, estimates were imprecise for serious, rare health outcomes. Home blood pressure measurement added to prenatal care visits was not associated with earlier diagnosis of a hypertensive disorder of pregnancy (104.3 vs 106.2 days), and incidence was not different between groups in 3 trials of reduced prenatal visit schedules. No harms of the different screening strategies were identified. CONCLUSIONS AND RELEVANCE: This review did not identify evidence that any alternative screening strategies for hypertensive disorders of pregnancy were more effective than routine blood pressure measurement at in-person prenatal visits. Morbidity and mortality from hypertensive disorders of pregnancy can be prevented, yet American Indian/Alaska Native persons and Black persons experience inequitable rates of adverse outcomes. Further research is needed to identify screening approaches that may lead to improved disease detection and health outcomes.
引用
- Henderson JT, Webber EM, Thomas RG, et al. Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023. PMID: 37721606. doi:10.1001/jama.2023.4934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。